AnaptysBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ANAB | ABCL | IMCR | ACRS | ANL | QTTB | |
|---|---|---|---|---|---|---|
| Market cap | 1.38B | 4.09B | 1.50B | 529.92M | 915.74M | 260.19M |
| P/E (TTM) | — | — | — | — | — | 2.8 |
| Forward P/E | 9.1 | -16.6 | -38.5 | -4.6 | -48.3 | -8.6 |
| Price/book | 129.3 | 4.3 | 3.6 | 4.0 | 4.3 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +116.83% | +122.84% | −9.15% | +88.48% | +746.43% | +111.14% |
| Today | +0.20% | +0.72% | −1.19% | −6.01% | −8.96% | +4.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ANAB news ›Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
AnaptysBio (NASDAQ:ANAB) Downgraded by Wall Street Zen to Hold
AnaptysBio (NASDAQ:ANAB - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Sunday, Wall Street Zen reports. Check Out Our Latest Stock Report on ANAB…
JPMorgan Chase & Co. Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $60.00
Check Out Our Latest Research Report on AnaptysBio AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company's programs are…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketbeat.com2
-
investors.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.